BrainCells Inc. Announces the Successful Completion of the Single Ascending Dose Study With BCI-838 and the Initiation of the Multiple Ascending Dose Study
2/29/2012 11:30:04 AM
More...
|
BrainCells Inc. Grabs Neuropsych Therapy from Proximagen Group in $51M Licensing Pact
8/4/2010 8:10:28 AM
More...
|
BrainCells Inc. Issued First U.S. Patent for Drug Combinations That Modulate Neurogenesis
4/29/2010 8:09:16 AM
More...
|
BrainCells Inc. Broadens Scientific Advisory Board Adding Drs. Edward Scolnick and David Holtzman
10/20/2009 11:06:22 AM
More...
|
Unlikely Treatment Identified by BrainCells Inc. Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression
7/27/2009 9:10:55 AM
More...
|
BrainCells Inc. Appoints Philip Jochelson, M.D. Chief Medical Officer and Jason Levin Chief Business Officer
3/30/2009 8:22:57 AM
More...
|
BrainCells Inc. Appoints David E. Thompson to Its Board of Directors
12/3/2008 9:02:43 AM
More...
|
BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
4/17/2008 4:35:45 PM
More...
|
BrainCells Inc. Expands Series B Financing to $50 Million
4/17/2008 4:32:01 PM
More...
|
BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing
3/10/2008 7:17:59 AM
More...
|
|